Cargando…

Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders

Rare, chronic diseases such as hemophilia and other congenital coagulation disorders require coordinated delivery of services for optimal outcomes. Hemophilia Treatment Centers (HTCs) are specialized, multidisciplinary health-care centers providing team-based care to meet the physical, psychosocial,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valentino, Leonard A, Baker, Judith R, Butler, Regina, Escobar, Miguel, Frick, Neil, Karp, Susan, Koulianos, Kollet, Lattimore, Susan, Nugent, Diane, Pugliese, Joseph N, Recht, Michael, Reding, Mark T, Rice, Michelle, Thibodeaux, Constance B, Skinner, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544265/ https://www.ncbi.nlm.nih.gov/pubmed/34707421 http://dx.doi.org/10.2147/JBM.S325031

Ejemplares similares

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
por: van Balen, Erna C., et al.
Publicado: (2021)

Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care
por: Roberts, Jonathan C., et al.
Publicado: (2022)

Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia
por: Lee, Soo Ok, et al.
Publicado: (2016)

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2018)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
por: von Drygalski, Annette, et al.
Publicado: (2022)

Use of coagulation screening in the critical care unit
por: Rice, A, et al.
Publicado: (2012)

Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study
por: Forsyth, Angela L, et al.
Publicado: (2015)

STUDIES ON BLOOD COAGULATION : IV. THE NATURE OF THE CLOTTING DEFICIENCY IN HEMOPHILIA
por: Eagle, Harry
Publicado: (1935)

Hemophilia Care in the Pediatric Age
por: Bertamino, Marta, et al.
Publicado: (2017)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
por: Krumb, Evelien, et al.
Publicado: (2021)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy
por: Mast, Alan E., et al.
Publicado: (2022)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Descriptive Epidemiology of Hemophilia and Other Coagulation Disorders in Mansoura, Egypt: Retrospective Analysis.
por: Al Tonbary, Youssef, et al.
Publicado: (2010)

Hemophilia trials in the twenty‐first century: Defining patient important outcomes
por: Konkle, Barbara A., et al.
Publicado: (2019)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

Mixing and administration times of bypassing agents: observations from the Dosing Observational Study in Hemophilia (DOSE)
por: Maahs, Jennifer, et al.
Publicado: (2014)

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019)

Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy
por: Heestermans, Marco, et al.
Publicado: (2017)

Quality of clinical studies present in the package inserts of coagulation factors used in the treatment of hemophilia
por: Araújo, Yasmin Gonçalves, et al.
Publicado: (2022)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

A Retrospective Analysis of the American Thrombosis and Hemostasis Network Dataset Describing Outcomes of Dental Extractions in Persons with Hemophilia
por: Messenger, Heather, et al.
Publicado: (2023)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
por: Wang, Michael, et al.
Publicado: (2022)

Coagulation assessment with thromboelastography during abdominal endovascular aneurysm repair in a patient with hemophilia A
por: Sato, Kazuki, et al.
Publicado: (2020)

Therapeutic Effects of Kefir Peptides on Hemophilia-Induced Osteoporosis in Mice With Deficient Coagulation Factor VIII
por: Yen, Chih-Ching, et al.
Publicado: (2022)

Recent Advances in the Treatment of Hemophilia: A Review
por: Marchesini, Emanuela, et al.
Publicado: (2021)

A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors
por: Veeranki, Sreenivas P, et al.
Publicado: (2021)

Multiple Comorbid Conditions among Middle-Aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care
por: Khleif, Aroub A., et al.
Publicado: (2011)

Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset
por: Recht, Michael, et al.
Publicado: (2022)

Point-of-care coagulation management in intensive care medicine
por: Meybohm, Patrick, et al.
Publicado: (2013)

Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management
por: Beny, Karen, et al.
Publicado: (2022)

Correction of the coagulation defect in hemophilia using a factor Xa variant with novel engineered protease function
por: Ivanciu, Lacramioara, et al.
Publicado: (2011)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Peri-cardiac surgery coagulation management in a severe hemophilia A patient: A case report
por: Xu, Hongfei, et al.
Publicado: (2019)

Optical sensing of anticoagulation status: Towards point-of-care coagulation testing
por: Tshikudi, Diane M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gpuvm9a131r2ltu0micgps3lbk